Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
prnewswire.com
news
2022-10-19 12:00:00

Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated
Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development
Additional data presented by Brii's licensing partners at IDWeek 2022 showcase breadth of Company's infectious disease program, spanning six therapeutic candidates and four potential disease indications

DURHAM, N.C. and BEIJING, Oct. 19, 2022 /PRNewswire/ --Â Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.
